Recently Visited
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} |
Score {{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
Most Searched
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} |
Score {{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
No Matches Found
Search results for {{searchTermHome}}
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} | Score
{{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
No Matches Found
No Matches Found
Finch Therapeutics Group, Inc.
Is Finch Therapeutics Group, Inc. overvalued or undervalued?
Loading...
Is Finch Therapeutics Group, Inc. technically bullish or bearish?
As of October 1, 2023, there is insufficient technical data for Finch Therapeutics Group, Inc. to determine a bullish or bearish outlook.
What does Finch Therapeutics Group, Inc. do?
Finch Therapeutics Group, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $5 million and a market cap of $21.84 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -158.08%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
![]( "Upgrade & View All Insights")
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Most Read